# Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

> **NCT03539952** · PHASE3 · COMPLETED · sponsor: **Orphalan** · enrollment: 77 (actual)

## Conditions studied

- Wilson Disease

## Interventions

- **DRUG:** Penicillamine (D1-W12)
- **DRUG:** TETA 4HCL (W12-60)
- **DRUG:** Penicillamine (W12-W60)
- **DRUG:** TETA 4HCL (60-<W108)

## Key facts

- **NCT ID:** NCT03539952
- **Lead sponsor:** Orphalan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-03
- **Primary completion:** 2020-08-19
- **Final completion:** 2022-01-18
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539952, "Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03539952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*